University Hospital Ulm

Running trials

• Recruiting

  Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

  NCT07378644· Phase 2/3· Source

• Not yet recruiting

  An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

  NCT06281847· Phase 1/2· Source

• Recruiting

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· Phase 3· Source

• Recruiting

  PROCARE - PROstate Cancer Real World Evidence Registry

  NCT06835218· Source

• Recruiting

  The ReTAVI Prospective Observational Registry

  NCT05601453· Source

• Recruiting

  The DefiPace Study

  NCT04804748· Source

• Active, not recruiting

  Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19

  NCT05619653· Phase 3· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559· Phase 3· Source

• Recruiting

  CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

  NCT05652569· Source

• Recruiting

  HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

  NCT02855476· Source

• Recruiting

  International HIT-MED Registry (I-HIT-MED)

  NCT02417324· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Huntington's disease2 recruiting
• Acute myeloid leukemia1 recruiting
• Atrial fibrillation1 recruiting
• Metastatic breast cancer1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

  NCT03399513· Phase 2· Source